Stable 211At-labeled radiopharmaceuticals for targeted α therapy
The SAt-Radio project aims to enhance the in vivo stability of 211At-labeled radiopharmaceuticals by exploring alternative bonding methods, improving cancer treatment efficacy.
Projectdetails
Introduction
Astatine (At) is the rarest naturally occurring element on Earth, exhibiting only short-lived radioisotopes. One of them, 211At, decays with a half-life of 7.2 hours by emission of a highly energetic alpha particle, making it one of the rare alpha emitters suitable for targeted alpha therapy (TAT) of cancers, if bound to an appropriate cancer targeting molecule.
Accessibility of 211At
Because the number of cyclotrons able to produce it has seen a significant rise in the past years, it is expected that 211At will become more accessible and play a major role in the development of TAT.
Chemical Properties of Astatine
Astatine belongs to the halogen elements, and despite more than 80 years since its discovery, many chemical properties remain to be discovered. This lack of knowledge is due to the absence of stable isotopes and the availability in minute amounts that preclude the use of standard analytical methods.
Research has shown that At behaves similarly to metals but also to halogens, forming bonds similar to its closest homologue, iodine, such as the carbon-At bond. This strategy is the main approach currently available to develop 211At-labeled radiopharmaceuticals.
Challenges with C-At Bond
Yet, a lack of in vivo stability of the C-At bond is often observed, resulting in the release of 211At before it reaches its target and leading to irradiation of healthy tissues. Improving this stability is therefore a major challenge that remains to be overcome in order to unleash the potential of 211At in cancer treatments.
Project Objective
In this context, the objective of the SAt-Radio project is to explore alternative bonding modalities to the C-At bond in order to develop novel radiolabeling approaches with improved in vivo stability.
The strategies developed will exploit both the halogen and the metallic character of At, using analytical and computational approaches that have recently become available, making it possible to elucidate the chemistry of this enigmatic element at the trace concentration it is available.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.357.165 |
Totale projectbegroting | € 2.357.165 |
Tijdlijn
Startdatum | 1-10-2023 |
Einddatum | 30-9-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSpenvoerder
- NANTES UNIVERSITE
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeted nanohorns for lithium neutron capture therapyTARLIT aims to enhance neutron capture therapy for cancer by using nanoparticles to deliver enriched lithium compounds, improving treatment precision and efficacy against tumors. | ERC Proof of... | € 150.000 | 2023 | Details |
Diagnose Alzheimer’s disease with isotopesThe project aims to utilize high-precision stable isotope measurements of metals to detect early stages of Alzheimer's disease, combining geochemistry with medical science for potential patenting. | ERC Proof of... | € 150.000 | 2023 | Details |
Deciphering the radiobiology of targeted radionuclide therapy: from subcellular to intra-tumoural analysesThis project aims to enhance targeted radionuclide therapies for metastatic cancer by elucidating radiobiological mechanisms and developing advanced imaging techniques to improve treatment strategies. | ERC Starting... | € 1.750.000 | 2022 | Details |
Highly Ionized Trapped 229-Thorium:A New Paradigm Towards a Nuclear ClockThe HITHOR project aims to develop a revolutionary nuclear clock using highly ionized thorium-229, enhancing precision in time measurement and enabling exploration of fundamental physics. | ERC Advanced... | € 2.498.963 | 2024 | Details |
Catalytic Atroposelective Synthesis for Revealing Elusive Bioactive Conformations and ShapesAtropShape aims to develop new catalytic methods for synthesizing diverse atropisomeric molecules to enhance drug discovery by exploring their unique pharmacological properties. | ERC Starting... | € 1.499.041 | 2025 | Details |
Targeted nanohorns for lithium neutron capture therapy
TARLIT aims to enhance neutron capture therapy for cancer by using nanoparticles to deliver enriched lithium compounds, improving treatment precision and efficacy against tumors.
Diagnose Alzheimer’s disease with isotopes
The project aims to utilize high-precision stable isotope measurements of metals to detect early stages of Alzheimer's disease, combining geochemistry with medical science for potential patenting.
Deciphering the radiobiology of targeted radionuclide therapy: from subcellular to intra-tumoural analyses
This project aims to enhance targeted radionuclide therapies for metastatic cancer by elucidating radiobiological mechanisms and developing advanced imaging techniques to improve treatment strategies.
Highly Ionized Trapped 229-Thorium:A New Paradigm Towards a Nuclear Clock
The HITHOR project aims to develop a revolutionary nuclear clock using highly ionized thorium-229, enhancing precision in time measurement and enabling exploration of fundamental physics.
Catalytic Atroposelective Synthesis for Revealing Elusive Bioactive Conformations and Shapes
AtropShape aims to develop new catalytic methods for synthesizing diverse atropisomeric molecules to enhance drug discovery by exploring their unique pharmacological properties.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Radom Emission Mitigation SystemAlfaRim ontwikkelt een grootschalige productiefaciliteit voor de zeldzame isotoop Actinium-225, gericht op het verbeteren van kankerbehandelingen via Targeted Alpha Therapy, met strikte naleving van veiligheidsnormen. | Mkb-innovati... | € 20.000 | 2020 | Details |
SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGSSMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery. | EIC Pathfinder | € 2.135.087 | 2024 | Details |
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug developmentATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Radom Emission Mitigation System
AlfaRim ontwikkelt een grootschalige productiefaciliteit voor de zeldzame isotoop Actinium-225, gericht op het verbeteren van kankerbehandelingen via Targeted Alpha Therapy, met strikte naleving van veiligheidsnormen.
SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGS
SMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery.
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness.